230 related articles for article (PubMed ID: 25365915)
1. High-quality production of human α-2,6-sialyltransferase in Pichia pastoris requires control over N-terminal truncations by host-inherent protease activities.
Ribitsch D; Zitzenbacher S; Augustin P; Schmölzer K; Czabany T; Luley-Goedl C; Thomann M; Jung C; Sobek H; Müller R; Nidetzky B; Schwab H
Microb Cell Fact; 2014 Sep; 13(1):138. PubMed ID: 25365915
[TBL] [Abstract][Full Text] [Related]
2. Combining expression and process engineering for high-quality production of human sialyltransferase in Pichia pastoris.
Luley-Goedl C; Czabany T; Longus K; Schmölzer K; Zitzenbacher S; Ribitsch D; Schwab H; Nidetzky B
J Biotechnol; 2016 Oct; 235():54-60. PubMed ID: 27018228
[TBL] [Abstract][Full Text] [Related]
3. Two N-terminally truncated variants of human β-galactoside α2,6 sialyltransferase I with distinct properties for in vitro protein glycosylation.
Luley-Goedl C; Schmoelzer K; Thomann M; Malik S; Greif M; Ribitsch D; Jung C; Sobek H; Engel A; Mueller R; Schwab H; Nidetzky B
Glycobiology; 2016 Oct; 26(10):1097-1106. PubMed ID: 27102286
[TBL] [Abstract][Full Text] [Related]
4. Expression of a mammalian alpha 2,6-sialyltransferase gene in Pichia pastoris.
Chotigeat W; Chayanunnukul W; Phongdara A
J Biotechnol; 2000 Jul; 81(1):55-61. PubMed ID: 10936660
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of sialoglycopolypeptide for potentially blocking influenza virus infection using a rat alpha2,6-sialyltransferase expressed in BmNPV bacmid-injected silkworm larvae.
Ogata M; Nakajima M; Kato T; Obara T; Yagi H; Kato K; Usui T; Park EY
BMC Biotechnol; 2009 Jun; 9():54. PubMed ID: 19500344
[TBL] [Abstract][Full Text] [Related]
6. The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death.
Amano M; Galvan M; He J; Baum LG
J Biol Chem; 2003 Feb; 278(9):7469-75. PubMed ID: 12499376
[TBL] [Abstract][Full Text] [Related]
7. Comparison of α2,6-sialyltransferases for sialylation of therapeutic proteins.
Janesch B; Saxena H; Sim L; Wakarchuk WW
Glycobiology; 2019 Sep; 29(10):735-747. PubMed ID: 31281932
[TBL] [Abstract][Full Text] [Related]
8. The structure of human α-2,6-sialyltransferase reveals the binding mode of complex glycans.
Kuhn B; Benz J; Greif M; Engel AM; Sobek H; Rudolph MG
Acta Crystallogr D Biol Crystallogr; 2013 Sep; 69(Pt 9):1826-38. PubMed ID: 23999306
[TBL] [Abstract][Full Text] [Related]
9. Enzymatic basis for N-glycan sialylation: structure of rat α2,6-sialyltransferase (ST6GAL1) reveals conserved and unique features for glycan sialylation.
Meng L; Forouhar F; Thieker D; Gao Z; Ramiah A; Moniz H; Xiang Y; Seetharaman J; Milaninia S; Su M; Bridger R; Veillon L; Azadi P; Kornhaber G; Wells L; Montelione GT; Woods RJ; Tong L; Moremen KW
J Biol Chem; 2013 Nov; 288(48):34680-98. PubMed ID: 24155237
[TBL] [Abstract][Full Text] [Related]
10. Engineering a bacterial sialyltransferase for di-sialylation of a therapeutic antibody.
Wang M; Wang Y; Liu K; Dou X; Liu Z; Zhang L; Ye XS
Org Biomol Chem; 2020 Apr; 18(15):2886-2892. PubMed ID: 32236230
[TBL] [Abstract][Full Text] [Related]
11. Exploring the acceptor substrate recognition of the human beta-galactoside alpha 2,6-sialyltransferase.
Legaigneur P; Breton C; El Battari A; Guillemot JC; Auge C; Malissard M; Berger EG; Ronin C
J Biol Chem; 2001 Jun; 276(24):21608-17. PubMed ID: 11279145
[TBL] [Abstract][Full Text] [Related]
12. Recognition of cell surface acceptors by two human alpha-2,6-sialyltransferases produced in CHO cells.
Donadio S; Dubois C; Fichant G; Roybon L; Guillemot JC; Breton C; Ronin C
Biochimie; 2003; 85(3-4):311-21. PubMed ID: 12770770
[TBL] [Abstract][Full Text] [Related]
13. Selective exo-enzymatic labeling of N-glycans on the surface of living cells by recombinant ST6Gal I.
Mbua NE; Li X; Flanagan-Steet HR; Meng L; Aoki K; Moremen KW; Wolfert MA; Steet R; Boons GJ
Angew Chem Int Ed Engl; 2013 Dec; 52(49):13012-5. PubMed ID: 24129959
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the enzymatic properties of mouse beta-galactoside alpha2,6-sialyltransferases, ST6Gal I and II.
Takashima S; Tsuji S; Tsujimoto M
J Biochem; 2003 Aug; 134(2):287-96. PubMed ID: 12966079
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory IgG production requires functional P1 promoter in β-galactoside α2,6-sialyltransferase 1 (ST6Gal-1) gene.
Jones MB; Nasirikenari M; Lugade AA; Thanavala Y; Lau JT
J Biol Chem; 2012 May; 287(19):15365-70. PubMed ID: 22427662
[TBL] [Abstract][Full Text] [Related]
16. Galatosylation and sialylation of mammalian glycoproteins produced by baculovirus-madiated gene expression in insect cells.
Yun EY; Goo TW; Kim SW; Choi KH; Hwang JS; Kang SW; Kwon OY
Biotechnol Lett; 2005 Jul; 27(14):1035-9. PubMed ID: 16132850
[TBL] [Abstract][Full Text] [Related]
17. Postnatal changes in sialylation of glycoproteins in rat liver.
Oda-Tamai S; Kato S; Akamatsu N
Biochem J; 1991 Nov; 280 ( Pt 1)(Pt 1):179-85. PubMed ID: 1741745
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of Drosophila sialyltransferase.
Koles K; Irvine KD; Panin VM
J Biol Chem; 2004 Feb; 279(6):4346-57. PubMed ID: 14612445
[TBL] [Abstract][Full Text] [Related]
19. 13C-sialic acid labeling of glycans on glycoproteins using ST6Gal-I.
Macnaughtan MA; Tian F; Liu S; Meng L; Park S; Azadi P; Moremen KW; Prestegard JH
J Am Chem Soc; 2008 Sep; 130(36):11864-5. PubMed ID: 18700760
[TBL] [Abstract][Full Text] [Related]
20. Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues.
Raju TS; Briggs JB; Chamow SM; Winkler ME; Jones AJ
Biochemistry; 2001 Jul; 40(30):8868-76. PubMed ID: 11467948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
